Adjuvant Clinical Trials

7 recruiting

Adjuvant Trials at a Glance

159 actively recruiting trials for adjuvant are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 66 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Beijing. Lead sponsors running adjuvant studies include Sun Yat-sen University, Fudan University, and Sixth Affiliated Hospital, Sun Yat-sen University.

Treatments under study

About Adjuvant Clinical Trials

Looking for clinical trials for Adjuvant? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adjuvant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adjuvant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 159 trials

Recruiting
Phase 2

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting
Phase 2

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

Neoadjuvant TreatmentThyroid Cancer
M.D. Anderson Cancer Center45 enrolled1 locationNCT06959511
Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting
Not Applicable

Prevention of CIPN Using Compressive Therapy

CIPN in Adjuvant Breast Cancer Patients
Martina Lojova100 enrolled1 locationNCT06823440
Recruiting
Not Applicable

Digital Mind-Body Therapy for Neoadjuvant Breast Cancer

Neoadjuvant Therapy
Fudan University66 enrolled1 locationNCT07541664
Recruiting
Phase 3

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Head & Neck CancerPostoperative Adjuvant TreatmentHead & Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University370 enrolled1 locationNCT07445048
Recruiting
Phase 2

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Primary Peritoneal CancerFallopian Tube CancerNeoadjuvant+1 more
AbbVie140 enrolled57 locationsNCT06890338
Recruiting

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled253 locationsNCT07128199
Recruiting
Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Minimal Residual DiseaseAdjuvant Chemotherapy
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting

Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors:

Adjuvant TherapyCDK4/6 Inhibitor
European Institute of Oncology750 enrolled18 locationsNCT07180693
Recruiting

Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Breast CancerNeoadjuvant TherapyInvasive Breast Carcinoma+2 more
Atlas University80 enrolled1 locationNCT07289282
Recruiting
Phase 2

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyLocally Advanced Rectal Cancer
Fudan University192 enrolled1 locationNCT06281405
Recruiting
Phase 2

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting

Prediction of Outcome to Neoadjuvant Therapy in Non-small Cell Lung Cancer(NSCLC)

Neoadjuvant TherapyNSCLC
Qian Chu500 enrolled2 locationsNCT07388771
Recruiting
Phase 3

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Renal Cell CarcinomaNeoadjuvant
ZHOU FANGJIAN298 enrolled8 locationsNCT05738694
Recruiting
Phase 1

An Antibody-armored Dendritic Cell in Patients With Solid Tumors

Adjuvant TherapySolid Cancers
Shanghai Cell Therapy Group Co.,Ltd8 enrolled1 locationNCT07479667
Recruiting
Not Applicable

Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer

Breast Cancer (Locally Advanced or Metastatic)Neoadjuvant ChemoimmunotherapyTattoo Skin Markers
All India Institute of Medical Sciences, Bhubaneswar30 enrolled1 locationNCT07478900
Recruiting
Phase 2

Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer

Neoadjuvant TherapyImmunotherapyTislelizumab+3 more
Seventh Medical Center of PLA General Hospital50 enrolled1 locationNCT07458529